Author

Mark G. Jones

Observed names: M G Jones, Mark G Jones

Institutions: University Hospital Southampton NHS Foundation Trust, National Institute for Health and Care Research, NIHR Southampton Respiratory Biomedical Research Unit, NIHR Southampton Biomedical Research Centre, University of Southampton

Observed institutions: University Hospital Southampton NHS Foundation Trust, National Institute for Health and Care Research, NIHR Southampton Respiratory Biomedical Research Unit, NIHR Southampton Biomedical Research Centre, University of Southampton

ORCID: 0000-0001-6308-6014

Observed ORCID: 0000-0001-6308-6014

OpenAlex ID: A5031476986

Multiscale mapping of venous remodelling in idiopathic pulmonary fibrosis

2026 · Daisuke Yamada, Huijuan Wang, et al. · bioRxiv (Cold Spring Harbor Laboratory)

When “Fibrotic” Does Not Mean Progressive: Interpreting a Trial of Nintedanib in Post-COVID-19 Lung Disease

2026 · Mark G Jones · Annals of the American Thoracic Society

Ultrafine particulate matter emitted from ships drives inflammation and susceptibility to viral infection

2026 · Natasha H.C. Easton, Lareb S.N. Dean, et al. · Environment International

A 3D multi-omics atlas of human lung fibrosis

2026 · Joseph Bell, Stephanie K. Robinson, et al.

Beneficial effects of the AT 2 receptor agonist buloxibutid (C21) against acute alveolar epithelial cell inflammation during antiviral responses

2026 · Franco Conforti, Joseph Bell, et al. · ERJ Open Research

Source-related composition and toxicological effects of shipping-associated particulate matter

2022 · L S Dean, N H Easton, et al. · 03.02 - Airway cell biology and immunopathology

Investigating the effects of metals within particulate matter in human alveolar epithelial cells

2022 · L S Dean, H S Vethakan-Raj, et al. · 03.02 - Airway cell biology and immunopathology

Works count: 7

Citation count:

H-index:

I10-index: